Peptide Therapeutics Market - Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2032
Overview
Peptide Therapeutics Market is expected to reach US$ 64.50 Bn. by 2032 from US$ 34.17 Bn in 2025, at a CAGR of 9.5% during the forecast period.
Peptide Therapeutics Market Overview:
Peptides are known for their high selectivity and efficacy while still being relatively safe and well-tolerated. As a result, peptides are receiving more attention in pharmaceutical research and development (R&D), with approximately 140 peptide therapeutics currently undergoing clinical trials. 
To know about the Research Methodology :- Request Free Sample Report
Peptide Therapeutics Market Dynamics:
The use of peptide molecules in the development of the COVID-19 vaccine is expected to increase, which will boost the market growth.
Vaxil announced the creation of a vaccine based on a proprietary signal peptide (SP) discovered using a bioinformatics tool in 2021. This strategy allows for the development of targeted therapies against cancer or infectious disease pathogens by using signal peptide domains on critical proteins.
Government funding for the use of peptides in the production of the COVID-19 vaccine is expected to provide a potential incentive for peptide adoption, which will potentially stimulate the growth of the peptide therapeutics market.
Growing cases of metabolic and infectious disorders are expected to stimulate market growth during the forecast period. The Centers for Disease Control and Prevention (CDC) states that about 34.2 million people in the United States were diagnosed with diabetes in 2022. Furthermore, the prevalence of diabetes continues to rise in comparison to previous decades, according to the same research. Diseases such as brain disorders and cancers are becoming more prevalent, resulting in higher healthcare costs.
Countries that are experiencing economic difficulties are more likely to implement cost-effective and reliable peptide therapeutics in order to reduce their healthcare costs. The American Cancer Society’s study suggests that there will be 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United States in 2021. The public awareness of peptide therapeutics and the implementation of favorable reimbursement policies by governments around the world are likely to influence consumers and doctors to seek out cost-effective therapeutic peptides in order to introduce experimental drugs for the treatment of serious disorders.
The global peptide therapeutics market is expected to be hampered by natural peptides' poor chemical and physical stability, as well as their limited circulating plasma half-life. However, since peptide drugs are administered by injection, low oral availability, and poor penetration of the intestinal mucosa are expected to limit market growth in the near future.
The development of new peptides are expected to provide lucrative growth opportunities for market players. CohBar, Inc., in 2021 announced new preclinical evidence that demonstrated the therapeutic potential of a novel CohBar peptide in a preclinical model of Idiopathic Pulmonary Fibrosis (IPF).
The report has profiled eighteen key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.
Recent Development: Peptide Therapeutics Market
| Exact Date | Company | Development | Impact |
|---|---|---|---|
| 29 January 2025 | Vertex Pharmaceuticals | The U.S. FDA approved Journavx (suzetrigine), a first-in-class non-opioid peptide-related pain medication for moderate-to-severe acute pain. | This approval provides a critical alternative to opioids, significantly reducing surgical pain and addressing a major unmet medical need in analgesic therapy. |
| 18 February 2025 | Hims & Hers Health, Inc. | Acquired a specialized U.S.-based peptide production facility in California to vertically integrate its personalized medicine supply chain. | The acquisition secures a consistent domestic supply of compounded GLP-1 and other therapeutic peptides, mitigating global shortage risks for the retail market. |
| 02 April 2025 | CordenPharma Group | Announced a €1 billion investment to construct a new greenfield plant near Basel with over 5,000 L SPPS capacity for peptide manufacturing. | This expansion drastically increases global production scale for metabolic and oncology peptides, supporting the industry "supercycle" driven by obesity treatments. |
| 21 August 2025 | Ionis Pharmaceuticals | Received FDA approval for Dawnzera (donidalorsen) as a preventive treatment for hereditary angioedema (HAE). | This approval introduces a long-acting therapeutic option that reduces the frequency of life-threatening swelling attacks, enhancing patient quality of life. |
| 19 September 2025 | Stealth BioTherapeutics | The FDA approved Forzinity (elamipretide), the first disease-specific peptide treatment for Barth syndrome. | The therapy improves mitochondrial function and muscle strength, representing a landmark milestone in the rare disease peptide pipeline. |
| 18 March 2026 | Johnson & Johnson (J&J) | The FDA approved ICOTYDE™ (icotrokinra), the first targeted oral peptide for the treatment of moderate-to-severe plaque psoriasis. | This breakthrough oral delivery technology eliminates the need for injections, drastically improving patient adherence and shifting the psoriasis treatment paradigm. |
Peptide Therapeutics Market Segment Analysis:
The Global Peptide Therapeutics Market is segmented on the basis of Type, Application and Route of Administration.
Based on Type, the branded segment held the largest market share in 2025. The segment growth is attributed to factors such as major pharmaceutical companies growing investments in R&D for the production of new drugs and high prescription rates. Generics, on the other hand, are expected to rise at a healthy rate over the forecast period. The use of generics is expected to be accelerated by rising healthcare spending and increased healthcare spending by the federal government.
Based on the Application, the cancer segment is expected to dominate the global market during the forecast period. The main factors driving this segment's dominance are an increase in the global incidence of cancer and an increase in the prescription of peptide therapeutics for cancer care. The growing demand for effective and fast-acting therapeutics is expected to boost growth even further.
The growing demand for effective and fast-acting therapeutics is expected to boost growth even further. Patients and healthcare practitioners are becoming more mindful of the negative effects of chemotherapy and radiation therapy, which is leading to a greater emphasis on alternative therapeutics such as peptide-based medications.
Peptide Therapeutics Market Regional Insights:
North America is expected to dominate the global market.
The market in North America is anticipated to dominate as a result of factors such as increased understanding of peptide therapeutics, the growing need for diagnostics in cancer and other diseases, and the expanding biotechnology industry. Increased government and industry spending on research and development is also expected to help peptide therapeutics maintain their supremacy in the coming years. Another factor such as the well-established biopharmaceutical and pharmaceutical industry in this region is a major driver of growth.
Asia Pacific is expected to witness lucrative growth during the forecast period.
Over the forecast period, the Asia-Pacific peptide therapeutics market is expected to expand significantly, owing to rising biotech companies and government healthcare spending, as well as the rising prevalence of cancer and nervous system disorders. These factors are anticipated to impact positively on the market growth in APAC.
The report also helps in understanding the Global Peptide Therapeutics Market dynamics, structure by analyzing the market segments and project the Global Peptide Therapeutics Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Peptide Therapeutics Market make the report investor’s guide.
Peptide Therapeutics Market Key Developments:
Bioniz Therapeutics Inc., a clinical-stage biopharmaceutical company developing first-in-class peptide treatments for immuno-inflammatory diseases, was acquired by Almirall, S.A. in January 2021.
Zealand Pharma A/S, a Copenhagen-based biotechnology company focusing on the discovery and production of novel peptide-based medicines, announced the acquisition of Encycle Therapeutics, Inc., a private Toronto-based biotech company with a unique platform technology that enables the rapid synthesis of macrocyclic peptides with enhanced drug-like properties, in October 2021.
Peptide Therapeutics Market Scope: Inquire before buying
| Peptide Therapeutics Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 34.17 USD Billion |
| Forecast Period 2026-2032 CAGR: | 9.5% | Market Size in 2032: | 64.5 USD Billion |
| Segments Covered: | by Type | Generic Branded |
|
| by Application | Gastrointestinal Disorders Neurological Disorders Metabolic Disorders Cancer Others |
||
| by Administration | Parenteral Oral |
||
| by End-Users | Hospitals Specialty Clinics Research Institutes Homecare Settings Others |
||
Peptide Therapeutics Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Peptide Therapeutics Market Key Players
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi
- Pfizer Inc.
- Novartis AG
- AstraZeneca
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- AbbVie Inc.
- Merck & Co. Inc.
- Johnson & Johnson
- Bristol-Myers Squibb
- Hoffmann-La Roche Ltd
- Ipsen Pharma
- Ferring Pharmaceuticals
- Ironwood Pharmaceuticals Inc.
- Radius Health Inc.
- The Medicines Company
- Bachem Holding AG
- Lonza Group AG
- PolyPeptide Group
- CordenPharma International
- MBX Biosciences
- Amicus Therapeutics
- Kiniksa Pharmaceuticals
- Exact Sciences Corporation
- Structure Therapeutics
- Viking Therapeutics
Frequently Asked Questions:
1. Which region has the largest share in Global Peptide Therapeutics Market?
Ans: North America region holds the highest share in 2025.
2. What is the growth rate of Global Peptide Therapeutics Market?
Ans: The Global Peptide Therapeutics Market is growing at a CAGR of 9.5% during forecasting period 2026-2032.
3. What is scope of the Global Peptide Therapeutics Market report?
Ans: Global Peptide Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. What is the study period of this market?
Ans: The Global Peptide Therapeutics Market is studied from 2025 to 2032.